Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase–4 Inhibitor vs Second-generation Sulfonylurea | Zendy

Hemin Lee | Zendy; Hye Jin Chung | Zendy; Ajinkya Pawar | Zendy; Elisabetta Patorno | Zendy; Dae Hyun Kim | Zendy

Open Access

Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase–4 Inhibitor vs Second-generation Sulfonylurea

Author(s) -

Hemin Lee,

Hye Jin Chung,

Ajinkya Pawar,

Elisabetta Patorno,

Dae Hyun Kim

Publication year - 2020

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2020.2158

Subject(s) - medicine , bullous pemphigoid , sulfonylurea , linagliptin , dipeptidyl peptidase 4 inhibitor , hazard ratio , incidence (geometry) , propensity score matching , type 2 diabetes , retrospective cohort study , diabetes mellitus , endocrinology , insulin , confidence interval , immunology , physics , antibody , optics

Despite several recent reports on the elevated risk of bullous pemphigoid in patients with type 2 diabetes treated with dipeptidyl peptidase-4 (DPP-4) inhibitors, evidence on the absolute risk and comparative safety against other antidiabetics is limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research